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In a recent paper entitled "A genetic-based algorithm for personalized resistance training", Jones et al. \[[@cit0001]\] proposed an algorithm of 15 performance-associated gene polymorphisms that they assert can determine an athlete's training response by predicting power and endurance potential. Two studies were conducted and involved athletes from several sports (e.g. swimming, ski/snowboard, squash, motorsport, and football players) undergoing an eight-week high- or low-intensity resistance training intervention comprising of one or two training sessions per week; participants continued sport-specific training and competition during the intervention period. The DNAFit Peak Performance Algorithm^™^ was used to calculate percentage power/endurance (P/E) score ratio using the 15 gene polymorphisms. Briefly, this involved the summation of assigning a point from 0-4, depending on the putative effect of each allele on power and/or endurance performance from the literature. Subjects were randomly assigned to either an endurance or power genotype training group involving low-intensity or high-intensity resistance training, either matched or mis-matched to the P/E ratio. The only genetic associations reported were between 5 of the 15 gene polymorphisms and training response as assessed by a countermovement jump (CMJ) and an aerobic-3 min cycle test (Aero3) determined before and after the intervention; albeit none of these associations reached the Bonferroni corrected significance. The authors also reported an increase in CMJ and Aero3 performance in the matched training group when assessed within each of the two training groups. On the basis of these results, the authors concluded that the DNAFit Peak Performance Algorithm^™^ can be used to guide personalised resistance-training prescription.

It is clear from the study design and the data provided by Jones et al. that there is no evidence to support these authors' assertions. The DNAFit Peak Performance Algorithm^™^ used by these authors comprises 15 polymorphisms in 14 genes (*ACE*, *ACTN3*, *ADRB2*, *AGT*, *BDKRB2*, *COL5A1*, *CRP*, *GABPB1*, *IL6*, *PPARA*, *PPARGC1A*, *TRHR*, *VDR* and *VEGFA*); most of which have been associated, albeit tentatively with sports performance in the literature (see [Table 1](#t0001){ref-type="table"} and \[[@cit0002]\]). To our knowledge, there is no direct evidence linking *CRP* (rs1205) polymorphism to endurance performance (not included in [Table 1](#t0001){ref-type="table"}); this specific polymorphism has recently been linked to a protective effect in the pathogenesis of cardiovascular heart disease in a meta-analysis \[[@cit0003]\]. Genetic findings to sports performance have been inconclusive to date, by primarily using the candidate gene approach in small sample sizes \[[@cit0004], [@cit0005]\]. As presented in [Table 1](#t0001){ref-type="table"}, there are positive and negative findings for some genetic markers but few of these polymorphisms have been replicated. Notably, for the *TRHR* gene variant, there is only one study supporting the link with lean body mass variation \[[@cit0006], [@cit0007]\] in 1000 US whites after several replication attempts in three different cohorts consisting of in total over 6000 white US and Chinese participants. The Vitamin D receptor *BsmI* (rs1544410) polymorphism has also been associated with muscle strength in elderly population in three studies but results remain inconclusive \[[@cit0008]\]. In contrast, *ACE* I/D and *ACTN3* R577X have been extensively studied and replicated to some degree in different populations \[[@cit0009]\], these two polymorphisms (together, separately, or part of an algorithm) do not predict training response \[[@cit0002], [@cit0010], [@cit0011]\].

###### 

Gene variants for endurance and power/strength athlete status (Adapted from \[[@cit0026]\]).

                                                                          Endurance   Power/Strength        
  --------------- --------------------------- ------------- ------------- ----------- ---------------- ---- ----
  ACE             Alu I/D (rs4646994)         I             D             16          12               7    7
  ACTN3           R577X (rs1815739 C/T)       577X          Arg577        4           14               12   5
  ADRB2           Gly16Arg (rs1042713 G/A)    16Arg         Gly16         2           1                1    \-
                  Gln27Glu (rs1042714 C/G)    \-            27Glu         \-          \-               1    \-
                                                                                                            
  AGT             Met235Thr (rs699 T/C)       \-            235Thr        \-          \-               2    \-
  BDKRB2          rs1799722 C/T               rs1799722 T   \-            1           \-               \-   \-
  COL5A1          rs12722 C/T (BstUI)         rs12722 T     \-            2           \-               \-   \-
  GABPB1 (NRF2)   rs7181866 A/G               rs7181866 G   \-            2           1                \-   \-
                                                                                                            
  IL6             -174 C/G (rs1800795 C/G)    \-            rs1800795 G   \-          \-               2    1
  PPARA           rs4253778 G/C               rs4253778 G   rs4253778 C   5           \-               2    1
  PPARGC1A        Gly482Ser (rs8192678 G/A)   Gly482        \-            4           3                \-   \-
  VEGFA           rs2010963 G/C               rs2010963 C   \-            1           \-               \-   \-

It is widely acknowledged that a single gene or a combination of a few genes (using genotype score) may explain a very low percentage of sports performance variation, for example, a 2-3% of sprinting performance variability may be explained by *ACTN3* genotype \[[@cit0011], [@cit0012]\]. Nevertheless, a recent meta-analysis of genome-wide association studies and their replications reported that common genetic variants could not discriminate elite endurance athletes from respective control populations (GENATHLETE, Japan, Australia, Poland, Russia, Spain, Kenya, and Ethiopia) \[[@cit0013]\]. Therefore, the research evidence to date to support the selection of any polymorphism is weak \[[@cit0011], [@cit0014], [@cit0015]\]. Timmons et al. and Bouchard et al. were the first to investigate training response using genome-wide exploration. Timmons et al. reported a discovery of 29 transcripts that predicted maximum oxygen uptake ($\overset{˙}{V}O_{2}\max$) training response, and these transcripts contained 11 single-nucleotide polymorphisms (SNPs) explaining 23% of the variance in gains in $\overset{˙}{V}O_{2}\max$ \[[@cit0016]\]. Bouchard et al. used data from the HERITAGE study (Health, Risk factors, Training and Genetics) and identified a set of 21 SNPs accounting for 49% of the variance in $\overset{˙}{V}O_{2}\max$ trainability \[[@cit0017]\]. However, none of the training-associated SNPs reported by Timmons et al. \[[@cit0016]\] were replicated by Bouchard et al. \[[@cit0017]\], nor were any of the "putative" training-associated SNPs reported in either study used in the DNAFit Peak Performance Algorithm^™^. The study by Jones et al. also highlights a number of methodological problems typically associated with the sport and exercise genomics literature \[[@cit0018]\] such as small sample size, sports variation and low number of training sessions. For example, both experiments in the Jones et al. employed very small sample sizes of 28 and 39 participants, respectively. Although authors stated that the sample sizes used were sufficient after power calculation, details of the power calculation were not provided and is most unlikely given the data presented and on the basis of other studies \[[@cit0019]--[@cit0021]\]. Progress towards developing training and/ or performance algorithms will require a paradigm shift in line with recent recommendations for international collaborations \[[@cit0022]\] such as the Athlome Project (see [www.athlomeconsortium.org](http://www.athlomeconsortium.org)). Such large-scale initiatives, designed specifically to overcome many of the limitations of small single-site studies will be necessary before attempting to derive and replicate training and performance algorithms.

In conclusion, while it is widely acknowledged that a favourable genotype combined with suitable training will enhance trainability and sporting performance, to date few (i.e. *ACTN3* and *ACE*) polymorphisms have been associated with an acceptable level of replication with endurance or power athletic performance, and none of these associations are strong enough to predict elite sports performance or trainability \[[@cit0014], [@cit0023], [@cit0024]\]. Currently, there is lack of scientific evidence supporting the predictive values of genetic tests (direct-to-consumer) for prescription of exercise training programmes, or for that matter, talent identification. Further studies with replication are needed in order for genetic variants to be used in personalised training prescription. As stated by Webborn et al., research findings should not be misinterpreted for commercial purposes \[[@cit0011]\]. Jones et al. \[[@cit0001]\] are premature in their attempt to demonstrate that a genetic test using DNAfit Peak Algorithm^™^ can determine the training response by predicting power and endurance potential. There are important limitations in their study design and interpretation of their results. Their suggestion of using a somewhat ambiguous algorithm to prescribe individualised training is premature. While acknowledging the difficulties in translating research discoveries, it is the responsibility of researchers to be cautious and not to over-interpret their research findings as this can motivate unsubstantiated commercial exploitation. Sarzynski et al. recently developed a framework for translating research discoveries that included useful information on sample size requirements and preferred technologies for discovery and replication phases of genetic research with particular reference to exercise genomics \[[@cit0025]\].
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